Market Intelligence, Clinical Progress, and High-Purity Reagents for Cachexia and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GFRAL drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GFRAL ECD-Fc / Mutant Protein. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified, HEK293 expressed (Native Glycosylation). | View GFRAL Products |
| Gene Delivery | GFRAL Lentivirus Premade Particles / Promise-ORF Lentivirus. Full-length ORF for stable cell line generation. Recommended for co-transfection with RET. | View GFRAL Products |
| Ligand Control | GDF15 Recombinant Protein. High purity (>95%), Sequence Verified. Essential ligand for competition and blocking assays. | View GDF15 Products |
| Benchmark Ab | Anti-GFRAL (Sequence of Biosimilar) for receptor binding; Anti-GDF15 (Ponesegromab Biosimilar) for ligand neutralization. Recombinant positive controls. | View GFRAL Products / View GDF15 Products |
| Co-receptor | RET Kinase / Full-Length Lentivirus. Essential signaling partner; required for functional GFRAL-mediated signal transduction. | View RET Products |
| Validator | GFRAL siRNA Set. For knockdown verification and assay specificity controls. | View GFRAL Products |
| Related Target A | GDF15. Primary endogenous ligand. Critical for blocking assays. | View GDF15 Products |
| Related Target B | RET. Essential signaling co-receptor for the GDF15-GFRAL axis. | View RET Products |
| Related Target C | ACVR2A (Activin Receptor Type IIA). Complementary cachexia pathway target; synergy potential with GFRAL inhibition. | View ACVR2A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Cynomolgus/Mouse GFRAL ECD-Fc orthologs available with >95% purity; sequence verified by mass spec. |
| Receptor-Ligand Complex Formation & Competition | High-purity GDF15 and RET proteins for reliable SPR/BLI binding kinetics and competition assays. |
| Co-receptor dependent signaling (RET required for function) | Lentivirus system for stable GFRAL+RET co-expression; preserves native conformation for calcium flux/cAMP assays. |
| Lack of Controls / Off-target GDNF family screening | Clinical Benchmark Antibodies included for assay standardization; Homolog panel (GFRa1, GFRa2) available for selectivity validation; Validated siRNA for specificity checks. |
Live GFRAL R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Target Research (Cachexia/Obesity)
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for GFRAL therapeutics is intensifying, driven by its central role in the GDF15 signaling pathway mediating cancer-associated cachexia (affecting 50-80% of cancer patients) and metabolic disorders. While the majority of clinical assets target the ligand GDF15 (e.g., Pfizer's Ponesegromab in Phase 3), the receptor GFRAL represents a strategic alternative with potentially improved CNS safety profiles. Major players are developing GFRAL antagonists to reverse cancer-induced weight loss, and agonists for obesity. As first-generation therapies approach late-stage readouts, the next wave of R&D is targeting optimal binding kinetics, prolonged half-life, combination with GLP-1 receptor agonists, and synergies with anabolic pathways (e.g., ActRII inhibition) to reverse muscle wasting. Bispecific antibodies (GDF15/ActRII) and small molecule inhibitors are emerging modalities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-GDF15 Monoclonal Antibody (Ligand Neutralization) | Pfizer (Ponesegromab), Novartis (Tropalencizumab), Eli Lilly (LY3463251) | Cancer Cachexia, Heart Failure | Ligand Neutralization & GFRAL Binding Competition (Need high-purity GDF15 and GFRAL ECD) |
| Anti-GFRAL Monoclonal Antibody (Receptor Blockade) | NGM Biopharmaceuticals (NGM120), Preclinical Biotechs | Cancer Cachexia (CNS-sparing) | Receptor Internalization & Signaling Blockade (Need Lentivirus cell lines with GFRAL+RET) |
| GFRAL Agonist Antibody | Janssen, Eli Lilly | Obesity, Metabolic Syndrome | Receptor Activation Assays (Need stable cell lines expressing GFRAL/RET for calcium flux/pERK) |
| Small Molecule Inhibitor | Calico Life Sciences / AbbVie | Metabolic Disease | Cell-based Reporter Assays (Need GFRAL+RET stable lines for high-throughput screening) |
| Bispecific Antibody (e.g., GDF15/ActRII) | Emerging Biotechs | Severe Cachexia | Dual Target Binding Validation (Need ACVR2A + GFRAL proteins and cross-reactive Abs) |